Navigation Links
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
Date:7/6/2009

BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia (DOI 10.1007/s00125-009-1415-7) showed similar effects on retinopathy and overall safety in the two treatment groups. This is the longest controlled study ever reported using insulin glargine.

Diabetic retinopathy is a major cause of blindness in patients with diabetes. It is a progressive disease that results from cellular proliferation within the eye. The stimulation of IGF1 receptors is involved in this process. In the study of patients with retinopathy, the progression of diabetic retinopathy was similar in the two treatment groups over the long-term course of treatment.

This indicates that Lantus does not have mitogenic effects different from the human NPH insulin within the eye.

"This 5-year study is the longest randomized controlled study with insulin glargine versus NPH human insulin," said lead investigator Julio Rosenstock, MD, Director of the Dallas Diabetes and Endocrine Center at Medical City and also Clinical Professor of Medicine, University of Texas Southwestern Medical School. "This study demonstrated no evidence of a greater risk of progression of retinopathy with insulin glargine."

The 5-year open-label study was specifically designed to further characterize the retinal safety profile of Lantus(R) versus NPH in 1024 patients (Lantus(R) once daily: 515 patients; NPH twice daily: 509 patients). Retinopathy progression was assessed using serial fundus photography.
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
2. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 20, 2015 Research and ... the "Global Pressure Relief Devices Market 2015-2019" ... Relief Devices market to grow at a CAGR of ... Pressure Relief Devices Market 2015-2019, has been prepared based ... experts. The report covers the Americas, and the APAC ...
(Date:7/27/2015)... 27, 2015  Attorney Advertising-- Bronstein, Gewirtz & Grossman, ... purchasers of the securities of AMAG Pharmaceuticals Inc. ... investors are advised to contact Peretz Bronstein ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its officers and/or directors have violated ...
(Date:7/27/2015)... , July 20, 2015 Research and Markets ... "Medical Device Regulation in Asia/Pacific Markets Seminar" ... the European Medical Device market is well established, the ... China , together with other countries ... the process of implementing, their own medical device regulations. ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2
... Myocor, Inc. announced that,the U.S. Food and ... Valvular and Ventricular Improvement Via iCoapsys Delivery ... evaluate the,safety and feasibility of the percutaneously ... valve insufficiency caused by left,ventricular dysfunction and ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... lab studies at Mayo Clinic focused,on multiple myeloma. ... Factor 5A gene technology to up-regulate apoptosis of ... for,encapsulation of Factor 5A to enhance the time ...
Cached Medicine Technology:Myocor Receives Approval for Percutaneous Trial 2Senesco Technologies Initiates Preclinical Studies for Cancer Target 2
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... ... entitled "Applying Data To Reduce Hospital Readmissions." , The Centers for Medicare and ... facility-level data used as part of their penalty calculation. Known as the QualityNet ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that ... loss can incur a lot of stress, pain, discomfort and embarrassment, which is why ... All-On-4™ treatment reaps the benefits of implants with the cost savings of dentures for ...
(Date:7/27/2015)... ... , ... According to an article published by the Times Free Press ... stemming from intravenous drug use. Intravenous drug use causes more overdoses and is responsible ... including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have witnessed ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... of fullerenes in medical and diagnostics applications is rapidly increasing and is driven ... and cancer treatment, they are increasingly being evaluated for use in bio implants. ...
(Date:7/27/2015)... ... ... Sher Fertility Institute, a national network of fertility clinics known ... their clinical team in Las Vegas. , Dr. Mark Severino joins ... Endocrinology teams in the region. , Combined Drs. Sher and Severino have more than ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 2Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 3
... the risk of developing breast cancer, says a new ... between handedness// and incidence of breast cancer in over ... 1941, reports science portal EurekAlert. ,They recorded ... economic status, smoking habits, family history of breast cancer, ...
... Wake Forest University Baptist Medical Center have begun a ... synthetic steroids to prevent premature babies//., ,Premature infants ... fully developed. Currently the best treatments are to give ... for as long as possible. ,Sheep will ...
... designed a plastic device which helps in prevention of ... patients//. The scarring in these cancer patients hinders the ... to reduce the risk of scarring in women undergoing ... ,Joan Thomas, is Macmillan Nurse specialist who has ...
... chemicals has been known to be associated with health ... But it is known not until recently that rheumatoid ... to mineraloil., ,The exact causative factor rheumatiod factor ... and environmental fcators have been help responsible to a ...
... might help lower the negative impact on a person's blood ... that job strain had a significant impact, both clinically and ... low marital cohesion, or a lack of support from a ... of blood pressure over one year. High marital cohesion in ...
... to lose the excess weight that one has to carry like ... best way is that adopted earlier that is the basic principle ... Obesity is a big problem these days., ,Calorie counting ... towards weight control., ,With so many dietary plans jostling for ...
Cached Medicine News:
Full plate covers seal all 24 MicroAmp tubes...
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Inquire...
... A soft, heat-resistant, aluminum foil film ... AlumaSeal II minimizes evaportaion and vapor ... need for heat-sealing devices or mats. ... sovents and reagents. Compared to other ...
Medicine Products: